Live feed19:00:00·1227dPRReleasevia QuantisnowCullinan Oncology Licenses U.S. Rights to the First Clinical-Stage B7H4 x 4-1BB Bispecific Immune Activator from Harbour BioMedByQuantisnow·Wall Street's wire, on your screen.CGEM· Cullinan Therapeutics Inc.Health Care
